AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $18.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$18.2M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 0 cutMore adding
Key stats
Fundamentals Sep 30- Open
- $125.72
- 52-wk high
- $132.60
- High
- $126.00
- 52-wk low
- $82.81
- Low
- $123.07
- Prev close
- $124.44
- Mkt cap
- $24.97B
- P/E
- 15.9x
- Volume
- 1.21M
- Fwd P/E
- 14.7x
- Beta
- 0.77
- P/S
- 4.3x
- P/B
- 4.1x
- Profit margin
- +27.7%
- Op margin
- +41.9%
- ROE
- +30.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about INCY filings
Are insiders buying or selling Incyte Corporation (INCY) stock?
Net selling: insiders sold $18.2M and bought $0 of INCY stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $18.2M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Cagnoni, Pablo J (President, Global Head of R&D), who sold $8.7M. The latest filing was on Sep 17, 2026.
Which members of Congress have traded INCY recently?
None. No member of Congress disclosed a INCY trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this INCY smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- TS
Two Sigma
$188.0M
added
- TS
Two Sigma
$35.5M
added
- JC
JPMorgan Chase
$42.4M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in INCY right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 59.1% above what analysts expected.
Earnings per share
$1.76 expected
Revenue
No comparable estimate
Company adjusted EPS
From the company's release
Compared on the analyst basis, which counts earnings differently from the company.
FY2026 guidance
$5.13B to $5.26B
No comparable estimate
Reports Oct 27, 2026, in 26 days
Estimates as of Sep 30, 2026
EPS expected
-$4.16 to -$2.34
Revenue expected
19 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.37B | $1.51B | $1.27B | $1.67B |
| Cost of what it sold | $99.0M | $121.1M | $104.5M | $105.0M |
| Gross profit | $1.27B | $1.39B | $1.17B | $1.57B |
| What it spent | ||||
| Research and development | $506.6M | $611.4M | $515.9M | $517.0M |
| Sales and admin | $329.1M | $390.4M | $328.1M | $351.7M |
| Total operating expenses | $835.7M | $1.00B | $844.0M | $871.2M |
| What was left | ||||
| Operating profit | $431.3M | $384.0M | $324.2M | $697.9M |
| Interest on debt | $592.0K | $582.0K | $569.0K | $581.0K |
| Profit before tax | $482.3M | $389.9M | $343.6M | $751.5M |
| Tax | $58.1M | $90.7M | $40.3M | $165.9M |
| Net profit | $424.2M | $299.3M | $303.3M | $585.6M |
| EBITDA | $506.9M | $414.5M | $368.0M | $752.1M |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Empery Digital Inc. SEC Filing (Sep 25, 2026)
NeutralSep 26Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older
NeutralSep 25About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment.
BullishSep 25Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
BullishSep 25Form 4 Incyte Corporation For: 25 September By Investing.com
NeutralSep 25Incyte Corporation (INCY) Stock Price Today: $125.74
BullishSep 25Atossa CEO to join Harvard panel on aging disease drug development and regulatory strategies
Leans bullishSep 25Incyte (INCY) withheld shares from its strategy chief for taxes at a reported $126.93 per share.
NeutralSep 24
Macro
20 macro signals shaping INCY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results